Gapping up
In reaction to earnings/guidance:
- ORGO +28% (guides Q3 and FY20 revs above consensus), CARS +14.1% (guides Q3 revenue above consensus), SNBR +6.8% (also says it intends to resume share repurchases in Q4), RDFN +2.4% (guidance update), WBA +1.9%, VSH +0.9% (raises guidance for Q3 revenue)
Other news:
- AVXL +32% (announces "positive" results from proof of concept controlled Phase 2 clinical trial evaluating ANAVEX2-73 (blarcamesine) in Parkinson's disease dementia)
- ARWR +10.2% (VRTX news seen as positive for ARWR)
- PGEN +3.6% (announced FDA clearance and successful technology transfer for its UltraPorator system)
- LIVX +3.1% (stock offering)
- DTIL +2.5% (announces U.S. Patent Trial and Appeal Board upholds Allogeneic CAR T patents)
- RDFN +2.4% (convertible notes offering)
- SAGE +1.7% (announces positive interim, topline zuranolone safety and tolerability data from open-label shoreline study in patients with MDD)
- VCYT +1.6% (announces two presentations)
- ACI +1.5% (declares first dividend)
- AMAG +1.5% (requests hearing to maintain Makena as treatment option; higher after Covis Group confirmed it commenced tender offer for all outstanding shares of AMAG Pharmaceuticals)
Analyst comments:
- ALKS +3.5% (upgraded to Buy from Neutral at Mizuho)
- SONO +1.4% (upgraded to Buy from Neutral at BofA Securities)
- VIAC +1.2% (upgraded to Overweight from Equal Weight at Barclays)
- USX +0.7% (upgraded to Buy from Hold at Stifel)
- EAT +0.5% (upgraded to Outperform from Market Perform at BMO Capital Markets)